Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | AKT1 | P31749 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PRKCH | P24723 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395054 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL245306 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL63754 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL272506 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL2128906 | 0.83 | AKT1 (0.69) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL2522867 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL2734284 | 0.82 | AKT1 (0.71) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL2734470 | 0.82 | AKT1 (0.71) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL8643482 | 0.82 | AKT1 (0.71) | SMN1; SMN2AKT1LMNAPRKD3PRKCG | |
| SCHEMBL8642035 | 0.82 | AKT1 (0.71) | SMN1; SMN2AKT1LMNAPRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7416848-B2 | DNA encoding SNORF25 receptor | H. LUNDBECK A/S (DK) | 2008-08-26 | — | — | US | disclosed |
| WO-2006062581-A2 | DELIVERY OF THERAPEUTIC RNAI AGENTS FOR TREATING RESTENOSIS | BENITEC, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060115454-A1 | Therapeutic RNAi agents for treating restenosis | BENITEC LIMITED (AU) | 2006-06-01 | — | — | US | disclosed |
| US-20030139590-A1 | DNA encoding SNORF25 receptor | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-07-24 | — | — | US | disclosed |
| US-20030125539-A1 | DNA encoding SNORF25 receptor | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-6468756-B1 | Methods of identifying compounds that bind to SNORF25 receptors | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-10-22 | — | — | US | disclosed |
| US-4551446-A | Use of synthetic phosphoglycerides possessing platelet activating properties as desensitizing agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1985-11-05 | — | — | US | disclosed |
| US-4504474-A | Synthetic phosphoglycerides possessing platelet activating properties | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1985-03-12 | — | — | US | disclosed |
| US-4329302-A | Synthetic phosphoglycerides possessing platelet activating properties | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115454-A1 | Therapeutic RNAi agents for treating restenosis | LDLR, TEK, TSG101 | SMN1; SMN2 2359/4885AKT1 2003/4885LMNA 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.